

PEER-REVIEWED PUBLICATIONS

1. Gini G, Cimminiello M, Galieni P, et al. **Advanced Stage Hodgkin Lymphoma: Patient Management.** Acta Bio-medica : Atenei Parmensis. 2020 May;91(S-5):5-12. DOI: 10.23750/abm.v91is-5.9913.
2. Roberto Mina, Angelo Belotti, Maria Teresa Petrucci, Renato Zambello, Andrea Capra, Giacomo Di Lullo, Sonia Ronconi, Norbert Pescosta, Mariella Grasso, Federico Monaco, Claudia Cellini, Marco Gobbi, Stelvio Ballanti, Paolo De Fabritiis, Maria Letizia Mosca-Siez, Monia Marchetti, Anna Marina Liberati, Massimo Offidani, Nicola Giuliani, Roberto Ria, Pellegrino Musto, **Alessandra Romano**, P. SONNEVELD, Mario Boccadoro, and Alessandra Larocca **Bortezomib-Dexamethasone as Maintenance Therapy or Early Retreatment at Biochemical Relapse Versus Observation in Relapsed/Refractory Multiple Myeloma Patients: A Randomized Phase II Study**, accepted 20-BCJ-0175RR
3. Tibullo D., Giallongo C., **Romano A.**, Vicario N., Barbato A., Puglisi F., Parenti R., Amorini A.M., Saab M., Tavazzi B., Mangione R., Brundo M.V., Lazzarino G., Palumbo G.A., Li Volti G., Lazzarino G., Di Raimondo F. **Mitochondrial functions, energy metabolism and protein glycosylation are interconnected processes mediating resistance to Bortezomib in multiple myeloma cells** Biomolecules 2020, 10, 696; doi:10.3390/biom10050696
4. Di Rosa M., Giallongo C., **Romano A.**, Tibullo D., Li Volti G., Musumeci G., Barbagallo I., Imbesi R., Castrogiovanni P. and Palumbo G.A. **Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients** Int. J. Mol. Sci. 2020, 21, 2926; doi:10.3390/ijms21082926
5. Toro, A., Parrinello, N.L., Schembari, E. et al. **Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions.** World J Emerg Surg 15, 17 (2020). <https://doi.org/10.1186/s13017-020-00299-z>
6. Markovic, U, Leotta, V, Tibullo, D, R. Giubbolini, **A. Romano** et al. **Serum free light chains and multiple myeloma: Is it time to extend their application?.** Clin Case Rep. 2019; 00: 1– 8. <https://doi.org/10.1002/ccr3.2636>
7. Iannitto E*, **Romano A***, Scalzulli PR, Bonanno V, Scalone R, Chiarenza A, Piroso MC, Caruso AL, Minoia C, Mantuano S, De Santis G, Salerno M, Crescimanno A, Porretto F, Li Gioi F, Ricciuti G, Greco A, Pavone E, Guarini A, Tarantini G, Mannina D, Consoli U, Cascavilla N, Di Raimondo F*, Musso M*. **Brentuximab vedotin in association with Bendamustine in refractory or multiple relapsed Hodgkin Lymphoma. A retrospective real-world study.** Eur J Haematol. 2020 Feb 27. doi: 10.1111/ejh.13400.
8. **Romano A**, Parrinello NL, Simeon V, Puglisi F, La Cava P, Bellofiore C, Giallongo C, Camiolo G, D'Auria F, Grieco V, Larocca F, Barbato A, Cambria D, La Spina E, Tibullo D, Palumbo GA, Conticello C, Musto P, Di Raimondo F. **High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.** Sci Rep. 2020 Feb 6;10(1):1983. doi: 10.1038/s41598-020-58859-x. PubMed PMID: 32029833.
9. Palumbo GA, Parrinello NL, Giallongo C, D'Amico E, Zanghì A, Puglisi F, Conticello C, Chiarenza A, Tibullo D, Raimondo FD, and **Romano A.** **Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.** Int J Mol Sci. 2019 Nov 1;20(21). pii: E5459. doi: 10.3390/ijms20215459. Review. PubMed PMID: 31683978; PubMed Central PMCID: PMC6862591.
10. Tibullo D, Longo A, Vicario N, **Romano A**, Barbato A, Di Rosa M, Barbagallo I, Anfuso CD, Lupo G, Gulino R, Parenti R, Li Volti GL, Palumbo GA, Di Raimondo FD, Giallongo C. **Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells.** Cancers (Basel). 2020 Jan 30;12(2). pii: E323. doi: 10.3390/cancers12020323. PubMed PMID: 32019102.
11. Parisi MS, Leotta S, **Romano A**, Del Fabro V, Martino EA, Calafiore V, Giubbolini R, Markovic U, Leotta V, Di Giorgio MA, Tibullo D, Di Raimondo F, Conticello C. **Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.** J Clin Med. 2019 Oct 16;8(10). pii: E1695. doi: 10.3390/jcm8101695. PubMed

PMID: 31623097

12. Tisi MC*, Ferrero S*, Dogliotti I*, Tecchio C, Carli G, Novo M, Stefani PM, Rattotti S, Balzarotti M, Marino D, Pelosini M, **Romano A**, Flenghi L, Zilioli VR, Calimeri T, Di Napoli A, Zanni M, Finolezzi E, Mosna F, Gini G, Mansueto G, Di Rocco A, Tomei G, Sgherza N, Olivieri J, Nassi L, Piazza F, Fama A, Greco A, Giannoccaro M, Mazzone AM, Visco C, Loseto G, Zaja F. **MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)**. *Hemasphere*. 2019 Oct 22;3(6):e305. doi: 10.1097/HS9.0000000000000305.eCollection 2019 Dec. PubMed PMID: 31976479; PubMed Central PMCID: PMC6924554.
13. Visco C*, Rodeghiero F*, **Romano A**, Valeri F., Merli M., Quaresimini G., Volpetti S., Santi R., Carli G., Lucchini E., Passamonti F., Rambaldi A., Motta G., Borchiellini A., D'Amore E., and Ruggeri M. **Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study**, *Blood*. 2019 Nov 14;134(20):1708-1711. doi: 10.1182/blood.2019001617.
14. D'Amico E., Zanghì A., **Romano A**., Sciandra M., Palumbo G.A. and Patti F. **The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis** *Cells* (2019), 8, 1114; doi:10.3390/cells8101114
15. Giallongo C., Tibullo D., Camiolo G., Parrinello N.L., **Romano A**., Puglisi F., Barbato A., Conticello C., Lupo G., Anfuso C.D., Lazzarino G., Li Volti G., Palumbo G.A and Di Raimondo F. **TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma** *Cell Death and Disease* (2019) 10:704 <https://doi.org/10.1038/s41419-019-1959-5>
16. Markovic U, Calafiore V, Martino E, Giubolini R, Parisi MS, **Romano A**, Del Fabro V, Di Raimondo F, Conticello C. **A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?** *Clin Case Rep*. 2019 Jul 15;7(9):1629-1636. doi: 10.1002/ccr3.2292.
17. **Romano A**, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C. **Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives**. *Front Oncol*. 2019 Aug 20;9:699. doi: 10.3389/fonc.2019.00699.
18. Conticello C, **Romano A**, Del Fabro V, Martino EA, Calafiore V, Sapienza G, Leotta V, Parisi MS, Markovic U, Garibaldi B, Leotta S, Cotzia E, Innao V, Mannina D, Neri S, Musso M, Scalone R, Cangialosi C, Acquaviva F, Cardinale G, Merenda A, Maugeri C, Uccello G, Poidomani M, Longo G, Carlisi M, Tibullo D, Di Raimondo F. **Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network**. *J Clin Med*. 2019 Jun 19;8(6). pii: E877. doi: 10.3390/jcm8060877.
19. Puglisi F., Parrinello N.L., Giallongo C., Cambria D., Camiolo G., Bellofiore C, Conticello C, Del Fabro V, Leotta V., Markovic U., Sapienza G., Barbato A, Scalese S, Tibullo D, Brundo MV, Palumbo GA, Di Raimondo F. and **Romano A**., **Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3** *Int. J. Mol. Sci*. 2019, 20(14), 3548; <https://doi.org/10.3390/ijms20143548>
20. Consoli ML, **Romano A**, Parrinello NL, Tambè L, Romeo MA, Salemi D, Santoro A, Di Raimondo F. **Unusual Karyotype in Acute Myelomonocytic Leukemia: A Case Report**. *Anticancer Res*. 2019 Aug;39(8):4329-4332. doi: 10.21873/anticancer.13599. PubMed PMID: 31366525.
21. Larocca A, Mina R, Offidani M, et al. **First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials**. *Haematologica*. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657.
22. Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, **Romano A**, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. **Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience**. *Clin Lymphoma Myeloma Leuk*. 2019 Mar 29. pii: S2152-2650(19)30084-9. doi: 10.1016/j.clml.2019.03.020
23. Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC,

- Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, **Romano A**, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL. **Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice**. *Oncologist*. 2019 Apr 2. pii: theoncologist.2018-0603. doi: 10.1634/theoncologist.2018-0603.
24. **Romano A**, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F. **Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma**. *Br J Haematol*. 2019 Feb 15. doi: 10.1111/bjh.15801. PMID: 30768678.
 25. Tirrò E., Massimino M., Romano C., Pennisi M.S., Stella S., Vitale, S.R., Fidilio A., Manzella, Parrinello N.L., Stagno F., Palumbo G.A., La Cava P., **Romano A.**, Di Raimondo F. and Vigneri P., **Chk1 Inhibition Restores Inotuzumab Ozogamicin Cytotoxicity in CD22-Positive Cells Expressing Mutant p53**, *Front Oncol*. 2019; 9: 57. PMID: PMC6387953
 26. Camiolo G, Tibullo D, Giallongo C, **Romano A**, Parrinello NL, Musumeci G, Di Rosa M, Vicario N, Brundo MV, Amenta F, Ferrante M, Copat C, Avola R, Li Volti G, Salvaggio A, Di Raimondo F, Palumbo GA. **α -Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload**. *Int J Mol Sci*. 2019 Jan 31;20(3). pii: E609. doi: 10.3390/ijms20030609. PubMed PMID: 30708965.
 27. **Romano A**, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Piroso MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F. **PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy**. *Expert Rev Mol Diagn*. 2018 May 3:1-9.
 28. Cerchione C, Nappi D, Pareto AE, **Romano A**, Martinelli V, Picardi M, Pane F, Catalano L. **Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience**. *Anticancer Drugs*. 2018 Apr;29(4):371-372.
 29. Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, **Romano A**, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A. **Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial**. *J Clin Oncol*. 2018 Jan 23;JCO2017752543. doi: 10.1200/JCO.2017.75.2543.
 30. Giallongo C, Parrinello NL, La Cava P, Camiolo G, **Romano A**, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, Tibullo D, Di Raimondo F. **Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib**. *J Cell Mol Med*. 2018 Feb;22(2):1070-1080.
 31. **Romano A**, et al, **The neutrophil-lymphocyte ratio (NLR) and the lymphocyte-monocyte ratio (LMR) predict progression free survival in patients with newly diagnosed multiple myeloma treated upfront with novel agents**, accepted *Blood Cancer Journal*, 17-BCJ-0285R
 32. Jurczak W, Ramanathan S, Giri P, **Romano A**, Mocikova H, Clancy J, Lechuga M, Casey M, Boni J, Giza A, Hess G. **Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma**. *Leuk. Lymphoma*. 2017 Aug 3:1-9. doi: 10.1080/10428194.2017.1357175. PubMed PMID: 28768446.
 33. Broccoli A, et al. **Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma**. *Haematologica*. 2017 Aug 3. pii: haematol.2017.171355. doi: 10.3324/haematol.2017.171355. PubMed PMID: 28775121.
 34. Pellegrini C. et al. **Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma** *Oncotarget*. May 2017 (in press)
 35. D'Urso D., Stefano A., **Romano A.**, Russo G., Cosentino S., Fallanca F., Gioè M., Attanasio M., Sabini M.G., Di Raimondo F. and Ippolito M. **Analysis of Metabolic Parameters Coming from Basal and**

- Interim PET in Hodgkin Lymphoma** Current Medical Imaging Reviews March 2017 Vol 13 (in press)
36. **Romano A**, Giallongo C., La Cava P, Parrinello N.L., Chiechi A., Vetro C., Tibullo D., Di Raimondo F., Liotta L, Espina V. and Palumbo G.A. **Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia** Front. Pharm. April 2017 (in press)
 37. Conticello C, Parisi M, **Romano A**, Calafiore V, Ancora F, La Fauci A, Consoli ML, Di Raimondo F. **Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma**. Future Oncol. 2017 Feb;13(5s):3-6. doi: 10.2217/fo-2016-0368.
 38. Ruggieri M, Praticò AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, Licciardello L, Milone P, Privitera G, Belfiore G, Di Pietro M, Di Raimondo F, **Romano A**, Chiarenza A, Muglia M, Polizzi A, Evans DG. **Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies**. Acta Otorhinolaryngol Ital. 2016 Oct;36(5):345-367. doi:10.14639/0392-100X-1093. PubMed PMID: 27958595; PubMed Central PMCID: PMC5225790
 39. **Romano A**, Consoli ML, Auteri G, Parisi M, Parrinello NL, Giallongo C, Tibullo D, Conticello C and Di Raimondo F. **R-ISS and NLR-ISS can Predict Time to Treatment in Smoldering Myeloma**. J Clin Trials 2016, 6:6 DOI: 10.4172/2167-0870.1000292
 40. Tibullo D, Caporarello N, Giallongo C, Anfuso CD, Genovese C, Arlotta C, Puglisi F, Parrinello NL, Bramanti V, **Romano A**, Lupo G, Toscano V, Avola R, Brundo MV, Di Raimondo F, Raccuia SA. **Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM)**. Nutrients. 2016 Oct 1;8(10). pii: E611. PubMed PMID: 27706074.
 41. Agostinelli C, Gallamini A, Stracqualursi L, Agati P, Tripodo C, Fuligni F, Sista MT, Fanti S, Biggi A, Vitolo U, Rigacci L, Merli F, Patti C, **Romano A**, Levis A, Trentin L, Stelitano C, Borra A, Piccaluga PP, Hamilton-Dutoit S, Kamper P, Zaucha JM, Malkowski B, Kulikowski W, Tajer J, Subocz E, Rybka J, Steidl C, Broccoli A, Argnani L, Gascoyne RD, d'Amore F, Zinzani PL, Pileri SA. **The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study**. Lancet Haematol. 2016 Oct;3(10):e467-e479. doi: 10.1016/S2352-3026(16)30108-9. PubMed PMID: 27692305.
 42. **Romano A**, Laura Parrinello N, Vetro C, Tibullo D, Giallongo C, La Cava P, Chiarenza A, Motta G, Caruso AL, Villari L, Tripodo C, Cosentino S, Ippolito M, Consoli U, Gallamini A, Pileri S, Di Raimondo F. **The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin Lymphoma**. Oncotarget. 2016 Sep 14. doi: 10.18632/oncotarget.12024. PubMed PMID: 27637084.
 43. Giallongo C*, **Romano A***, Parrinello NL, La Cava P, Brundo MV, Bramanti V, Stagno F, Vigneri P, Chiarenza A, Palumbo GA, Tibullo D, Di Raimondo F. **Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients**. PLoS One. 2016 Jul 8;11(7):e0158392. doi: 10.1371/journal.pone.0158392. eCollection 2016.
 44. **Romano A**, Parrinello N.L. and Di Raimondo F. (2016) **Granulocytic Myeloid Derived Suppressor Cells are Increased in Multiple Myeloma and can Predict outcome in Patients Treated upfront with Lenalidomide**. Ann. Hematol. Oncol. 3 (2): 1078-1085.
 45. La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella R, Martino M, **Romano A**, Di Raimondo F, Gallamini A, Carcassi C, Caocci G. **The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma**. J Hematol Oncol. 2016 Mar 16;9(1):26.
 46. Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, Di Raimondo C, Conticello C, Chiarenza A, Palumbo GA, Avola R, **Romano A**, Di Raimondo F. **Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)**. Oncotarget. 2016 Mar 7. doi: 10.18632/oncotarget.7969. PubMed PMID: 26967390.
 47. Tibullo D, Barbagallo I, Giallongo C, Vanella L, Conticello C, **Romano A**, Saccone S, Godos J, Di Raimondo F, Li Volti G. **Heme Oxygenase-1 Nuclear Translocation Regulates Bortezomib-Induced Cytotoxicity and Mediates Genomic Instability in Myeloma Cells**. Oncotarget. 2016 Feb

22. doi: 10.18632/oncotarget.7563.
48. Magliano A., Camarda M., Lombardo S.F., Di Martino R., Cascio M., **Romano A.**, Minafra L., Russo G., Gilardi M., Di Raimondo F., Scalese S., La Magna A. **Elution time changes due to anomalous DEP effects in microchannels under uniform and non-uniform electric fields**, Sensing and Bio-Sensing Research, Available online 17 February 2016, ISSN 2214-1804
 49. Di Martino R, Camarda M, Cascio M, Gallo M, Magliano A, Baldo S, **Romano A**, Minafra L, Forte G I, Russo G, Gilardi M C, Di Raimondo F, Scalese S and La Magna A, **Analysis of the role of elution buffers on the separation capabilities of dielectrophoretic devices**, Sensing and Bio-Sensing Research, Available online 8 December 2015, ISSN 2214-1804
 50. S. Baldo, S. Buccheri, A. Ballo, M. Camarda, A. La Magna, M.E. Castagna, **A. Romano**, D. Iannazzo, F. Di Raimondo, G. Neri, S. Scalese, **Carbon nanotube-based sensing devices for human arginase-1 detection**, (2015), doi:10.1016/j.sbsr.2015.11.011
 51. **Romano A**, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I. **Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents**. Ann Hematol. 2015 Nov;94(11):1875-83.
 52. Vetro C, Bonanno G, Giulietti G, **Romano A**, Conticello C, Chiarenza A, Spina P, Coppolino F, Cunsolo R, Raimondo FD. **Rare gastrointestinal lymphomas: The endoscopic investigation**. World J Gastrointest Endosc. 2015 Aug 10;7(10):928-49.
 53. Vetro C, Rosso R, Palmucci S, Russello M, Colletta G, Romeo MA, Ximenes B, **Romano A**, Palumbo GA, Di Raimondo F. **Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome**. J Clin Apher. 2015 Sep 28. doi: 10.1002/jca.21434
 54. Tibullo D, Di Rosa M, Giallongo C, La Cava P, Parrinello NL, **Romano A**, Conticello C, Brundo MV, Saccone S, Malaguarnera L, Di Raimondo F. **Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells**. Front Pharmacol. 2015 Oct 14;6:226. doi: 10.3389/fphar.2015.00226.
 55. Vetro C, **Romano A**, Ancora F, Coppolino F, Brundo MV, Raccuia SA, Puglisi F, Tibullo D, La Cava P, Giallongo C, Parrinello NL. **Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells**. Front Oncol. 2015 May 21;5:104
 56. Milone G, Camuglia MG, Avola G, Di Marco A, Leotta S, Cupri A, Spina P, **Romano A**, Spina E, Azzaro MP, Berritta D, Parisi M, Tripepi G. **Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment**. Exp Hematol. 2015 Feb 20. pii: S0301-472X(15)00042-9. doi: 10.1016/j.exphem.2015.02.002.
 57. Parrinello N, Di Raimondo F, **Romano A**. **Myeloid Derived Suppressor Cells in Multiple Myeloma**. **Exp Rev Immunol Vaccine Information** 2014; 1: 14-20.
 58. Vetro C, **Romano A**, Amico I, Conticello C, Motta G, Figuera A, Chiarenza A, Di Raimondo C, Giulietti G, Bonanno G, Palumbo GA, Di Raimondo F. **Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up**. World J Gastroenterol. 2014 Sep 28;20(36):12993-3005
 59. **Romano A**, Marescalco MS, Liardo C, Villari L, Vetro C, Conticello C, Di Raimondo F, Ferlito S. **Oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature**. Case Rep Hematol.2014;2014:529452.
 60. **Romano A**, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Raimondo FD. **Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy**. Br J Haematol. 2014 Nov 7. doi: 10.1111/bjh.13198. [Epub ahead of print] PubMed PMID: 25376846.
 61. Giallongo C, Parrinello N, Tibullo D, La Cava P, **Romano A**, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F. **Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients**. PLoS One. 2014 Jul 11;9(7):e101848. doi: 10.1371/journal.pone.0101848. eCollection 2014. PubMed PMID: 25014230.
 62. **Romano A**, Conticello C, Cavalli M, Vetro C, La Fauci A, Parrinello NL, Di Raimondo F. **Immunological Dysregulation in Multiple Myeloma Microenvironment**. Biomed Res Int. 2014;2014:198539. Epub 2014 Jun 11. Review. PubMed PMID: 25013764; PubMed Central PMCID: PMC4071780.

63. **Romano A**, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Di Martina V, Schinocca E, La Fauci A, Parrinello NL, Chiarenza A, Di Raimondo F. **Salvage Therapy of Multiple Myeloma: The New Generation Drugs**. *Biomed Res Int*.2014;2014:456037. Epub 2014 May 19. Review. PubMed PMID: 24967371; PubMed Central PMCID: PMC4055245.
64. **Romano A**, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, La Nasa G. **Immunological deregulation in classic hodgkin lymphoma**. *Mediterr J Hematol Infect Dis*. 2014 Jun 1;6(1):e2014039. doi: 10.4084/MJHID.2014.039. eCollection 2014. Review. PubMed PMID: 24959336; PubMed Central PMCID: PMC4063611.
65. **Romano A**, Chiarenza A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Cunsolo R, Palumbo GA, Di Raimondo F. **Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients**. *Eur J Haematol*. 2014 Mar 27. doi: 10.1111/ejh.12325.
66. Gambella M, Rocci A, Passera R, Gay F, Omedè P, Crippa C, Corradini P., **Romano A**, Rossi D. et al. **High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib**. *Haematologica*. 2014;99(2):e14-e6.
67. Vetro C, Chiarenza A, **Romano A**, Amico I, Calafiore V, Di Raimondo C, Coppolino F, Di Raimondo F. **Prognostic Assessment and Treatment of Primary Gastric Lymphomas: How Endoscopic Ultrasonography Can Help in Tailoring Patient Management**. *Clin Lymphoma Myeloma Leuk*. 2013 Nov 15. PubMed PMID: 24369919.
68. Vetro C, Giulietti G, Calafiore V, **Romano A**, Di Raimondo F. **A snapshot of asparaginase-induced liver insufficiency**. *Eur J Haematol*. 2013 Dec 14. PubMed PMID: 24329712.
69. Conticello C., Vetro C., **Romano A**, Amato G. Schinocca L., Cosentino S., Ippolito M., Giutolisi R., Di Raimondo F., **Abnormal F-18 fluorodeoxyglucose uptake of the lung in immunocompromised lymphoma patients in complete remission: report of two cases and revision of literature**, *European Journal of Inflammation*, 2013, Vol. 11, no. 3, 893-899
70. Conticello C, Giuffrida R, Parrinello N, Buccheri S, Adamo L, Sciuto MR, Colarossi C, Aiello E, Chiarenza A, **Romano A**, Salomone E, Gulisano M, Giustolisi R, Di Raimondo F. **CD200 expression in patients with Multiple Myeloma: Another piece of the puzzle**. *Leuk Res*. 2013 Sep 23. doi:pji: S0145-2126(13)00287-7. 10.1016/j.leukres.2013.08.006. PubMed PMID: 24183830.
71. Gallamini A, Di Raimondo F, La Nasa G, **Romano A**, Borra A, Greco M. **Standard therapies versus novel therapies in Hodgkin lymphoma**. *Immunol Lett*. 2013 Oct 16. doi:pji: S0165-2478(13)00134-X. 10.1016/j.imlet.2013.09.011. PubMed PMID: 24140162.
72. Savage SA, Pulsipher MA, **Romano A**, Berlyne D. **Aplastic Anemia & MDS International Foundation (AA&MDSIF): bone marrow failure disease scientific symposium 2012**. *Leuk Res*. 2013 Jul;37(7):848-51. doi:10.1016/j.leukres.2013.04.013.
73. **Romano A**, Conticello C, Di Raimondo F. **Bortezomib for the treatment of previously untreated multiple myeloma**. *Immunotherapy* 5(4), 327–352 (2013).
74. **Romano A**, Uccello G., Spina P., Cunsolo R., Vetro C. and Di Raimondo F. **Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients** *Current Cancer Therapy Reviews, Volume 9, Number 1, February 2013, pp. 1-7(7)*
75. Giuffrida G., Cingari R., Parrinello N., **Romano A**, Triolo A., Franceschino M. and Di Raimondo F. **Bone turnover markers in patients with type 1 Gaucher disease** *Hematology Reports* 2012; volume 4: e21- DOI: 10.4081/hr.2012.e21
76. **Romano A**, A. Chiarenza, U. Consoli, C. Conticello, S. Forte, G. Uccello, C. Vetro, M. Cavalli, F. Coppolino, G. A. Palumbo, and F. Di Raimondo **Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma** *Ann Oncol_2012* doi:10.1093/annonc/mds531 PMID: 23136226
77. Chiechi A, Mueller C, Boehm KM, **Romano A**, Benassi MS, Picci P, Liotta LA, Espina V **Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples**. *Biotechniques* 2012 Sep;0(0):1-7 PMID: 22946677
78. **Romano A**, Vetro C, Donnarumma D, Forte S, Ippolito M and Di Raimondo F. **Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma**.

Haematologica 2012;97(6):e21-23.doi:10.3324/haematol.2012.064576

79. Vetro C., **Romano A.**, Chiarenza A., Conticello C., Donnarumma D., Gorgone A, Coppolino F., Palumbo G.A., Bonanno G. and Di Raimondo F. **Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.** *Hematol. Oncol.* 2011 Dec 20. doi: 10.1002/hon.1022.
80. **Romano A.**, Vetro C, Adriani M. **Advances in understanding regulatory myeloid cells.** *Cancer Biol Ther.* 2011 Jun 1;11(11). PubMed PMID: 21474999.
81. Conticello C, Giuffrida R, Adamo L, Anastasi G, Martinetti D, Salomone E, Colarossi C, Amato G, Gorgone A, **Romano A et al.** **NF-kappa B localization in multiple myeloma plasma cells and mesenchymal cells.** *Leukemia Research* 2011, **35**(1):52-60.
82. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, **Romano A**, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omedè P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A. **Complete response correlates with long-term progression-free and overall survivals in elderly myeloma treated with novel agents: analysis of 1175 patients.** *Blood* 2011
83. Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, **Romano A**, Chiarenza A, Palumbo GA, Di Raimondo F. **Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of Chronic Myeloid Leukemia cells.** *Eur J Haematol* 2011
84. Palumbo A, Cavo M, Bringhen S, Zamagni E, **Romano A**, et. al. **Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide:A Phase III, Open-Label, Randomized Trial.** *J Clin Oncol.* 2011 Jan 31. PubMed PMID: 21282540.
85. Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, **Romano A**, Di Raimondo F, Condorelli DF: **Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML.** *Leukemia Research* 2010, **34**(11):1539-1542.
86. Barresi V, **Romano A**, Musso N, Capizzi C, Consoli C, Martelli MP, Palumbo G, Di Raimondo F, Condorelli DF: **Broad Copy Neutral-Loss of Heterozygosity Regions and Rare Recurring Copy Number Abnormalities in Normal Karyotype-Acute Myeloid Leukemia Genomes.** *Genes Chromosomes & Cancer* 2010, **49**(11):1014-1023.

BOOK CHAPTERS

1. **A. Romano**, V. Barresi, C. Consoli, N. Musso, C. Capizzi, G. A. Palumbo, F. Di Raimondo and D. F. Condorelli, **Conventional and molecular cytogenetic techniques and their application in Myelodysplastic Syndromes**, in *Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy*- Chapter 6, NOVA Publishers, ISBN 978-1-62417-580-0, edited by Hamid Sayar (Indiana University Simon Cancer Center, Indianapolis, IN, USA)
2. **Romano A.**, **Gammopatie monoclonali**, in Bosi A., De Stefano V., Di Raimondo F., La Nasa G *MANUALE DI MALATTIE DEL SANGUE*, 2012, Elsevier, ISBN: 9788821432620.
3. Vetro C., **Romano A.**, Palumbo G.A., Bonanno G. and Di Raimondo F. **Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature** in: *Ultrasound Imaging - Medical Applications* ISBN 978-953-307-279-1, Edited by: Igor V. Minin and Oleg V. Minin, InTech (2011)
4. Di Raimondo F, **Romano A**, **Sangue**, in Tamburino - Castellino - Di Maria - Di Raimondo - Ettore - Fiore - Purrello, *Il Rasario- Manuale di Semeiotica Medica*, 2010, Idelson – Gnocchi ISBN: 8879475274
5. Di Raimondo F, **Romano A**, Schinocca L Chiarenza A, **Rischio di infertilità nella terapia medica dei tumori ematologici**, in Banna G. L., Catalano F., Condorelli R., Peccatori F., *Preservazione della fertilità in oncologia*, 2009, Laurencin editor, www.medinews.it/bin.